ESTRO 2024 - Abstract Book

S438

Clinical - Biomarkers

ESTRO 2024

With a median follow-up of 13.1 months, 33 patients diagnosed with HCC underwent SBRT during the specified period. Serum IGF-1 levels, collected prospectively prior to the procedure, were available for 32 patients with their characteristics are presented in Table 1. Our analysis revealed significant correlations between IGF-1 levels and both age (R=0.37, p=0.036) and CPS (R=- 0.38, p=0.033). In contrast, no significant correlations were observed between IGF-1 levels and tumor volume, performance status, or AFP levels. To categorize patients, we applied a cut-off point of 62.2 ng/ml, dichotomizing them into 'IGF-1 low' (<62.2 ng/ml) and 'IGF-1 high' (>62.2 ng/ml) groups. Notably, patients with low IGF-1 levels exhibited significantly lower OS than those with high IGF-1 levels (p-value: 0.024), while PFS demonstrated similar outcomes between the two groups.

Characteristics

Number of Patients

32

Median serum IGF-1 level (range)

62.4 (21.3-158.9) ng/ml

Median Age (range)

74 (60-86)

Gender: -

12 20

Female

- Male

Median

prescribed

physical

dose

40

(24-50)

Gy

Median prescribed dose as EQD2 α/ β_10

60 (35.5-83.3) Gy

Median number of fractions

5 (3-8)